1. Home
  2. KALV vs GDOT Comparison

KALV vs GDOT Comparison

Compare KALV & GDOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • GDOT
  • Stock Information
  • Founded
  • KALV N/A
  • GDOT 1999
  • Country
  • KALV United States
  • GDOT United States
  • Employees
  • KALV N/A
  • GDOT N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • GDOT Finance: Consumer Services
  • Sector
  • KALV Health Care
  • GDOT Finance
  • Exchange
  • KALV Nasdaq
  • GDOT Nasdaq
  • Market Cap
  • KALV 523.1M
  • GDOT 609.1M
  • IPO Year
  • KALV N/A
  • GDOT 2010
  • Fundamental
  • Price
  • KALV $11.18
  • GDOT $13.08
  • Analyst Decision
  • KALV Strong Buy
  • GDOT Hold
  • Analyst Count
  • KALV 4
  • GDOT 4
  • Target Price
  • KALV $29.00
  • GDOT $10.75
  • AVG Volume (30 Days)
  • KALV 247.5K
  • GDOT 322.3K
  • Earning Date
  • KALV 12-05-2024
  • GDOT 11-07-2024
  • Dividend Yield
  • KALV N/A
  • GDOT N/A
  • EPS Growth
  • KALV N/A
  • GDOT N/A
  • EPS
  • KALV N/A
  • GDOT N/A
  • Revenue
  • KALV N/A
  • GDOT $1,574,307,000.00
  • Revenue This Year
  • KALV N/A
  • GDOT N/A
  • Revenue Next Year
  • KALV $539.64
  • GDOT $9.86
  • P/E Ratio
  • KALV N/A
  • GDOT N/A
  • Revenue Growth
  • KALV N/A
  • GDOT 7.36
  • 52 Week Low
  • KALV $7.21
  • GDOT $7.30
  • 52 Week High
  • KALV $16.88
  • GDOT $13.58
  • Technical
  • Relative Strength Index (RSI)
  • KALV 46.78
  • GDOT 66.83
  • Support Level
  • KALV $10.78
  • GDOT $11.16
  • Resistance Level
  • KALV $12.12
  • GDOT $13.58
  • Average True Range (ATR)
  • KALV 0.72
  • GDOT 0.46
  • MACD
  • KALV -0.07
  • GDOT 0.15
  • Stochastic Oscillator
  • KALV 41.20
  • GDOT 79.51

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

About GDOT Green Dot Corporation $0.001 par value

Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.

Share on Social Networks: